Malaria Journal

official impact factor 3.49

Open Access Highly Access Research

Artesunate – amodiaquine combination therapy for falciparum malaria in young Gabonese children

Sunny Oyakhirome1, Marc Pötschke1, Norbert G Schwarz1, Jenny Dörnemann1, Matthias Laengin1, Carmen O Salazar1, Bertrand Lell1,2, Jürgen FJ Kun2, Peter G Kremsner1,2 and Martin P Grobusch1,3*

Author Affiliations

1 Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon

2 Department of Parasitology, Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany

3 Infectious Diseases Unit, Division of Clinical Microbiology and Infectious Diseases, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

For all author emails, please log on.

Malaria Journal 2007, 6:29 doi:10.1186/1475-2875-6-29

Published: 12 March 2007

Abstract

Background

Artesunate-amodiaquine combination for the treatment of childhood malaria is one of the artemisinin combination therapies (ACTs) recommended by National authorities in many African countries today. Effectiveness data on this combination in young children is scarce.

Methods

The effectiveness of three daily doses of artesunate plus amodiaquine combination given unsupervised (n = 32), compared with the efficacy when given under full supervision (n = 29) to children with falciparum malaria were assessed in an unrandomized study.

Results

61 patients analysed revealed a PCR-corrected day-28 cure rate of 86 % (25 of 29 patients; CI 69 – 95 %) in the supervised group and 63 % (20 of 32 patients; CI 45 – 77 %) in the unsupervised group. The difference in outcome between both groups was statistically significant (p = 0.04). No severe adverse events were reported.

Conclusion

The effectiveness of this short course regimen in young children with falciparum malaria could be augmented by increased adherence and improved formulation.